[PREPRINT] A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer Disease

Posiphen (buntanetap) - Annovis Bio

Mar 22, 2024